Ascend Capital’s Forte Biosciences FBRX Stock Holding History

Ascend Capital’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-99	Closed	-$464K	–	225
2017 Q3	$464K	Buy	+99	New	+$441K	0.02%	160

Other funds holding FBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ascend Capital's FBRX Position: Q4 2017 in Review

Ascend Capital sold out of Forte Biosciences (FBRX) in Q4 2017, closing a stake of 99 shares — an estimated $464K sold.

Ascend Capital first reported a position in FBRX in Q3 2017 and held it in 1 quarter. The position peaked at $464K in Q3 2017. 57 funds tracked by Wall St. Rank hold FBRX as of Q4 2017.

Ascend Capital reported no remaining Forte Biosciences position as of Q4 2017 after selling out during the quarter.
Ascend Capital sold 99 Forte Biosciences shares in Q4 2017, an estimated $464K.
Ascend Capital first reported a position in Forte Biosciences in Q3 2017 and held it in 1 quarter.
Ascend Capital's Forte Biosciences position peaked at $464K in Q3 2017.
57 funds tracked by Wall St. Rank held Forte Biosciences as of Q4 2017.

Based on Ascend Capital's 13F filing for Q4 2017, filed 13 Feb 2018.